Z H A Sadik1, E H J Voormolen2, P R A M Depauw3, B Burhani3, W A Nieuwlaat4, J Verheul5, S Leenstra5, R Fleischeuer6, P E J Hanssens7. 1. Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Utrecht University Medical Center, Utrecht, The Netherlands. Electronic address: z.sadik@etz.nl. 2. Department of Neurosurgery, Utrecht University Medical Center, Utrecht, The Netherlands. 3. Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. 4. Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. 5. Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. 6. Department of Pathology, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. 7. Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands.
Abstract
OBJECTIVE: It is still not clear whether Gamma Knife radiosurgery (GKRS) for nonfunctional pituitary adenomas should be used as a standard adjuvant postoperative therapy or applied when there is documented progression of the remnant on follow-up magnetic resonance imaging. METHODS: We performed a retrospective study of patients with nonfunctional pituitary adenomas who underwent primary surgery and GKRS between 2002 and 2015. Patients were divided into 2 groups on the basis of the GKRS indication: adjuvant treatment (GKRS ≤6 months postoperatively) or delayed treatment (GKRS if documented progression occurred on the follow-up magnetic resonance imaging). RESULTS: Fifty patients were included and grouped based on adjuvant (n = 13) or delayed (n = 37) GKRS following primary surgery. The adjuvant and delayed groups had 10-year actuarial tumor control rates of 92% and 96% (P = 0.408), respectively. The 10-year actuarial endocrinologic control rate was 82% for the adjuvant group and 49% for the delayed group (P = 0.597). None of the patients developed any new neurologic deficit post-GKRS. GKRS-induced complications (intratumoral bleeding and tumoral tissue inflammation) occurred in 6% of the patients, of whom 4% were in the delayed group and 2% in the adjuvant group. CONCLUSION: Adjuvant treatment with GKRS yields the same high long-term tumor control as delayed GKRS. Neither adjuvant nor delayed GKRS induced additional neurologic complications. There is a trend that adjuvant GKRS induces less additional endocrinologic deficits compared with delayed GKRS.
OBJECTIVE: It is still not clear whether Gamma Knife radiosurgery (GKRS) for nonfunctional pituitary adenomas should be used as a standard adjuvant postoperative therapy or applied when there is documented progression of the remnant on follow-up magnetic resonance imaging. METHODS: We performed a retrospective study of patients with nonfunctional pituitary adenomas who underwent primary surgery and GKRS between 2002 and 2015. Patients were divided into 2 groups on the basis of the GKRS indication: adjuvant treatment (GKRS ≤6 months postoperatively) or delayed treatment (GKRS if documented progression occurred on the follow-up magnetic resonance imaging). RESULTS: Fifty patients were included and grouped based on adjuvant (n = 13) or delayed (n = 37) GKRS following primary surgery. The adjuvant and delayed groups had 10-year actuarial tumor control rates of 92% and 96% (P = 0.408), respectively. The 10-year actuarial endocrinologic control rate was 82% for the adjuvant group and 49% for the delayed group (P = 0.597). None of the patients developed any new neurologic deficit post-GKRS. GKRS-induced complications (intratumoral bleeding and tumoral tissue inflammation) occurred in 6% of the patients, of whom 4% were in the delayed group and 2% in the adjuvant group. CONCLUSION: Adjuvant treatment with GKRS yields the same high long-term tumor control as delayed GKRS. Neither adjuvant nor delayed GKRS induced additional neurologic complications. There is a trend that adjuvant GKRS induces less additional endocrinologic deficits compared with delayed GKRS.
Authors: P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños Journal: Clin Transl Oncol Date: 2018-04-05 Impact factor: 3.405
Authors: Aasim N Maldar; Sanjeev Pattankar; Basant K Misra; Phulrenu H Chauhan; Milind Sankhe; Ketan Desai; N F Shah Journal: J Neurooncol Date: 2022-05-20 Impact factor: 4.130
Authors: Rupesh Kotecha; Arjun Sahgal; Muni Rubens; Antonio De Salles; Laura Fariselli; Bruce E Pollock; Marc Levivier; Lijun Ma; Ian Paddick; Jean Regis; Jason Sheehan; Shoji Yomo; John H Suh Journal: Neuro Oncol Date: 2020-03-05 Impact factor: 12.300